Search Results

You are looking at 1 - 10 of 49 items for :

  • "erythropoietin" x
  • All content x
Clear All

References 1. Akbulut S , Gurbilek M , Kryici A , Akoz M , Alintepe L , Karakuscu A , Topcu C : The effect of erythropoietin application on erythrocyte Na,K-ATPase activities in patients with diabetic polyneuropathy

Restricted access

Kumar, S. M., Yu, H., Fong, D. és mtsai: Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res., 2006, 16 , 275–283. Fong D

Open access

Lin, F. K., Suggs, S., Lin, C. H. és mtsai: Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 1985, 82 , 7580–7582. Lin C. H. Cloning and

Restricted access

Kakuk, Gy., Kárpáti, I., Mátyus, J.: Recombinant human erythropoietin in the therapy of anemia in haemodialysed patients. [Hemodializált betegek anaemiájának kezelése rekombináns humán

Restricted access

J Wilson J Seidenfeld 2006 Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353

Restricted access

Abstract  

Human recombinant erythropoietin (EPO) was successively labeled with [111In]-indium chloride after conjugation with freshly prepared cyclic DTPA-dianhydride (ccDTPA). The best results of the conjugation were obtained by the addition of 100 i.u. of an EPO pharmaceutical solution (in phosphate buffer, pH 7.5) to a glass tube pre-coated with DTPA-dianhydride (0.01 mg) at 25 °C with continuous mild stirring for 30 minutes. Radio thin layer chromatography (RTLC), instant thin layer chromatography (ITLC) and high performance liquid chromatography (HPLC) showed overall radiochemical purity of higher than 95% at optimized conditions (specific activity = 1.2–1.5 GBq/mg, labeling efficiency 80%). Preliminary in vivo studies in normal rat model was performed to determine the biodistribution of the radiotracer up to 1 hour using scarification. The high kidney uptake of the tracer was consistent with the reported EPO receptor distribution.

Restricted access

Abstract  

The aim of the present study was to demonstrate the possible transplacental transmission of 131I labeled recombinant human erythropoietin (131I-rh-EPO) in pregnant rats and its distribution through maternal and fetal organs. Six Wistar Albino Rats in their pregnancy of 18 days were used 131I labeled recombinant human erythropoietin (specific activity = 2.4 μCi/IU) was injected into the tail vein of rats. After 30 minutes labeled erythropoietin infusion maternal stomach, kidney, lung, liver, brain and heart as well as fetus were removed. Then, the same organs were removed from each fetus. Measuring weight of maternal and fetal organs as well as placenta were followed by radioactivity count via Cd(Te) detector. 131I labeled recombinant human erythropoietin was found to be able to pass rat placenta and its distribution order in fetal organs was similar to those of maternal organs. Besides, as measurements were performed closer to cornu uteri, uptakes were decreasing in every fetus and its corresponding placenta.

Restricted access

Spallone V, Maiello MR, Kurukulasuriya N et al.: Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients? Diabet. Med. 21, 1174–1180 (2004) Kurukulasuriya N

Restricted access
Acta Physiologica Hungarica
Authors: J. Balla, V. Jeney, Zs. Varga, E. Komódi, E. Nagy, and Gy. Balla

244 Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am. J. Kidney Dis. 29, 565–568 (1997

Restricted access
Magyar Onkológia
Authors: József Tímár, Miklós Kásler, Alexandra Heringh, Miklós Soós, Dóra Mathiász, Anna Romány, Adrienn Józsa, László Szilák, Tamás Forrai, László Patthy, and Gábor Kovács

, Bereczky , B , Gilly , R et al. 2008 Recombinant human erythropoietin-alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels Strahlenther Oncol 184 1 – 7 . 9

Restricted access